Eli Lilly's Alzheimer's drug approved in Japan
Sept 24 (Reuters) -Eli Lilly LLY.N said on Tuesday Japan's health ministry has approved donanemab, its drug for Alzheimer's disease, providing patients with another treatment option after Eisai 4523.T and Biogen's BIIB.O Leqembi received the nod in September last year.
Lilly said Japan is the second major market in which the drug has received approval, after the United States where it is sold under the same brand name Kisunla.
The Alzheimer's Association estimates that more than 4.6 million people are living with dementia in Japan and it is expected to rise significantly as the country's population ages.
According to Japan's National Institute of Population and Social Security Research, people aged over 65 are expected to account for 32.3% of the country's population by 2035.
Like Leqembi, Lilly's Kisunla is designed to clear an Alzheimer's-related protein called beta-amyloid from the brain.
In a large, late-stage trial, Kisunla slowed the progression of memory and thinking problems by 29% compared with a placebo. It also caused brain swelling in nearly a quarter of patients and brain bleeding in nearly a third, but most cases were mild.
Kisunla is sold with the FDA's strongest "boxed" safety warning on its prescribing label in the U.S., flagging the risk of potentially dangerous brain swelling and bleeding, similar to Leqembi.
Unlike Leqembi, Kisunla has finite dosing, which allows patients to stop taking the treatment once brain scans no longer show amyloid plaques.
A Japanese health ministry panel in August had recommended approval for Lilly's treatment.
Alzheimer's is the most common cause of dementia and accounts for about 60%-70% of the cases, according to the World Health Organization.
Lilly estimates that the number of patients with dementia could be more than 5 million in Japan by 2030.
Reporting by Puyaan Singh in Bengaluru; Editing by Krishna Chandra Eluri and Vijay Kishore
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
